FMT-Female match

FMT-Male match

 

Transsexuals (n=29)

DETECT (n=72)

 

Transsexuals (n=21)

DETECT (n=44)

 

 

mean

SD

mean

SD

p

mean

SD

mean

SD

p

Age

34.7

7.5

31.8

7.5

0.074

35.7

8.3

34.4

7.9

0.530

Age at diagnosis

24.7

7.8

-

-

-

24.7

7.8

-

-

-

Length of HT

4.9

4.6

-

-

-

4.9

4.6

-

-

-

Diseases

n

%

n

%

p

n

%

n

%

p

Cardiovascular

5

17.2

9

12.5

0.536

5

25.0

9

20.5

0.686

Respiratory

5

17.2

7

9.7

0.299

3

15.0

5

11.4

0.687

Neurological

1

3.5

10

13.9

0.162

0

0.0

4

9.1

-

Endocrine

5

17.2

34

47.2

0.008

2

10.0

17

38.6

0.033

Gastroenterological

7

24.1

9

12.5

0.156

5

25.0

4

9.1

0.105

Urinary

2

6.9

5

6.9

0.993

1

5.0

5

11.4

0.435

Tumoural

2

6.9

8

11.1

0.527

1

5.0

1

2.3

0.574

Immune-mediated

2

6.9

5

6.9

0.993

1

5.0

2

4.6

0.937

BMI (mean/SD)

25.4

4.8

24.9

5.2

0.666

25.2

4.8

27.5

4.6

0.062

There is no indication of an increased risk associated with hormone treatment in transsexual patients. The values presented are means ± standard deviation (SD) or total number (n) and percentage (%). Up to 3 controls were matched for each patient. Differences in the number of transsexual patients within the same row of the table are due to differences in the availability of age-matched control subjects. FMT: female-to-male transsexuals; p: p-value.
Table 1: Lifetime comorbidities in female-to-male transsexuals in comparison to age- and gender-matched comparison groups from the DETECT-Cohort.